Clinical Trial Update: Ixazomib in the Prophylaxis of Chronic Graft-versus-host Disease. [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 clinical trial evaluating ixazomib for prophylaxis of chronic graft-versus-host disease after hematopoietic stem cell transplantation.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Graft-versus-host Disease
• Multiple Myeloma

Drugs mentioned

• ixazomib (ixazomib)

Snippet

Sponsor: Fundación Pública Andaluza para la gestión de la Investigación en Sevilla | Conditions: Hematopoietic Stem Cell Transplantation, Multiple Myeloma | Phase 1, Phase 2 | Status: ACTIVE_NOT_RECRUITING